Resistance to antimalarial drugs: Molecular, pharmacologic, and clinical considerations

Pediatric Research

Volumn 65, Issue SUPPL. 5, 2009, Pages

  Travassos, Mark A ^a   Laufer, Miriam K ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; BENFLUMETOL; CHLOROQUINE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; HALOFANTRINE; MEFLOQUINE; MULTIDRUG RESISTANCE PROTEIN; PROGUANIL; PROTEIN ATP6; PROTOZOAL PROTEIN; PYRIMETHAMINE; QUININE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SULFADOXINE; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIMALARIAL DRUG RESISTANCE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG QUALITY; ENDEMIC DISEASE; HEMOGLOBINOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM OVALE; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTIMALARIALS; DRUG RESISTANCE; HOST-PATHOGEN INTERACTIONS; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 68049140634     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1203/PDR.0b013e3181a0977e     Document Type: Review

References (72)

1. World Health Organization 2008 World Malaria Report 2008. WHO, Geneva
2. Trape JF, Legros F, Ndiaye P, Konate L, Bah IB, Diallo S, Verdier F, Hatin I, Le Bras J 1989 Chloroquine-resistant Plasmodium falciparum malaria in Senegal. Trans R Soc Trop Med Hyg 83:761
3. Zucker JR, Ruebush TK, Obonyo C, Otieno J, Campbell CC 2003 The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, western Kenya. Am J Trop Med Hyg 68:386-390 (Pubitemid 38230635)
4. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM 2001 Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol 17:582-588
5. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR 2002 Epidemiology of drug-resistant malaria. Lancet Infect Dis 2:209-218
6. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, O'Neill PM, Bray PG, Ward SA, Krishna S 2003 Artemisinins target the SERCA of Plasmodium falciparum. Nature 424:957-961
7. ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S 1993 Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 76:85-95
8. White NJ 2008 Qinghaosu (artemisinin): the price of success. Science 320:330-334
9. Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ 2004 Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother 48:1329-1334 (Pubitemid 38405489)
10. Ittarat W, Pickard AL, Rattanasinganchan P, Wilairatana P, Looareesuwan S, Emery K, Low J, Udomsangpetch R, Meshnick SR 2003 Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am J Trop Med Hyg 68:147-152 (Pubitemid 38240537)
11. Wellems TE, Walker-Jonah A, Panton LJ 1991 Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7. Proc Natl Acad Sci USA 88:3382-3386
12. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE 2000 Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 6:861-871
13. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D 2001 A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344:257-263 (Pubitemid 32108530)
14. Durand R, Jafari S, Vauzelle J, Delabre JF, Jesic Z, Le Bras J 2001 Analysis of pfcrt point mutations and chloroquine susceptibility in isolates of Plasmodium falciparum. Mol Biochem Parasitol 114:95-102
15. Lakshmanan V, Bray PG, Verdier-Pinard D, Johnson DJ, Horrocks P, Muhle RA, Alakpa GE, Hughes RH, Ward SA, Krogstad DJ, Sidhu AB, Fidock DA 2005 A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J 24:2294-2305
16. Valderramos SG, Fidock DA 2006 Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci 27:594-601 (Pubitemid 44572395)
17. Cooper RA, Hartwig CL, Ferdig MT 2005 pfcrt is more than the Plasmodium falciparum chloroquine resistance gene: a functional and evolutionary perspective. Acta Trop 94:170-180
18. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK 1997 Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 176:1590-1596
19. Gregson A, Plowe CV 2005 Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 57:117-145 (Pubitemid 40283971)
20. Ter Kuile FO, van Eijk AM, Filler SJ 2007 Effect of sulfadoxine- pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 297:2603-2616
21. Nzila A, Ochong E, Nduati E, Gilbert K, Winstanley P, Ward S, Marsh K 2005 Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? Trans R Soc Trop Med Hyg 99:341-346
22. Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, Baruch DI, Magill AJ, Su XZ 2002 Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 418:320-323
23. Wellems TE, Plowe CV 2001 Chloroquine-resistant malaria. J Infect Dis 184:770-776
24. Clyde DF 1954 Observations on monthly pyrimethamine (daraprim) prophylaxis in an East African village. East Afr Med J 31:41-46
25. Maiga O, Djimde AA, Hubert V, Renard E, Aubouy A, Kironde F, Nsimba B, Koram K, Doumbo OK, Le Bras J, Clain J 2007 A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa. J Infect Dis 196:165-172
26. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T 2004 Intercontinental spread of pyrimethamine-resistant malaria. Science 305:1124
27. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV 2003 Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187:1870-1875
28. Nkhoma S, Molyneux M, Ward S 2007 Molecular surveillance for drug-resistant Plasmodium falciparum malaria in Malawi. Acta Trop 102:138-142
29. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV 2006 Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355:1959-1966 (Pubitemid 44708015)
30. Rohrbach P, Sanchez CP, Hayton K, Friedrich O, Patel J, Sidhu AB, Ferdig MT, Fidock DA, Lanzer M 2006 Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum. EMBO J 25:3000-3011
31. Duah NO, Wilson MD, Ghansah A, Abuaku B, Edoh D, Quashie NB, Koram KA 2007 Mutations in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance genes, and treatment outcomes in Ghanaian children with uncomplicated malaria. J Trop Pediatr 53:27-31
32. Woodrow CJ, Krishna S 2006 Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance. Cell Mol Life Sci 63:1586-1596 (Pubitemid 44252173)
33. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP 2005 In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 191:1014-1017
34. Alker AP, Lim P, Sem R, Shah NK, Yi P, Bouth DM, Tsuyuoka R, Maguire JD, Fandeur T, Ariey F, Wongsrichanalai C, Meshnick SR 2007 Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg 76:641-647 (Pubitemid 351627700)
35. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJ, Krishna S, White NJ, Nosten F 2006 Molecular and pharmacological determinants of the therapeutic response to artemetherlumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 42:1570-1577
36. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S 2004 Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364:438-447
37. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA 2006 Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis 194:528-535
38. Nair S, Miller B, Barends M, Jaidee A, Patel J, Mayxay M, Newton P, Nosten F, Ferdig MT, Anderson TJ 2008 Adaptive copy number evolution in malaria parasites. PLoS Genet 4:e1000243
39. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O 2005 Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366:1960-1963
40. Zhang G, Guan Y, Zheng B, Wu S, Tang L 2008 No PfATPase6 S769N mutation found in Plasmodium falciparum isolates from China. Malar J 7:122
41. Mugittu K, Genton B, Mshinda H, Beck HP 2006 Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania. Malar J 5:126
42. Ferreira ID, Lopes D, Martinelli A, Ferreira C, Do Rosario VE, Cravo P 2007 In vitro assessment of artesunate, artemether and amodiaquine susceptibility and molecular analysis of putative resistance-associated mutations of Plasmodium falciparum from Sao Tome and Principe. Trop Med Int Health 12:353-362
43. Stepniewska K, White NJ 2008 Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 52:1589-1596 (Pubitemid 351614647)
44. Nyunt MM, Plowe CV 2007 Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance. Clin Pharmacol Ther 82:601-605
45. Watkins WM, Mosobo M 1993 Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 87:75-78 (Pubitemid 223049894)
46. Hastings IM, Ward SA 2005 Coartem (artemether-lumefantrine) in Africa: the beginning of the end? J Infect Dis 192:1303-1304
47. Djimde AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, Dama S, Ouologuem D, Dicko A, Doumbo OK 2008 Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg 78:455-461 (Pubitemid 351845197)
48. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Bjorkman A 2006 Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol 6:309-314
49. Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Bjorkman A 2005 Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 41:1079-1086
50. Barnes KI, Lindegardh N, Ogundahunsi O, Olliaro P, Plowe CV, Randrianarivelojosia M, Gbotosho GO, Watkins WM, Sibley CH, White NJ 2007 World Antimalarial Resistance Network (WARN) IV: clinical pharmacology. Malar J 6:122 (Pubitemid 47561491)
51. White NJ, Stepniewska K, Barnes K, Price RN, Simpson J 2008 Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol 24:159-163
52. Barnes KI, Watkins WM, White NJ 2008 Antimalarial dosing regimens and drug resistance. Trends Parasitol 24:127-134
53. Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ 2000 Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother 44:3414-3424 (Pubitemid 33009503)
54. Kofoed PE, Lopez F, Johansson P, Sandstrom A, Hedegaard K, Aaby P, Rombo L 2002 Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau. Am J Trop Med Hyg 67:28-31
55. Ursing J, Schmidt BA, Lebbad M, Kofoed PE, Dias F, Gil JP, Rombo L 2007 Chloroquine resistant P. falciparum prevalence is low and unchanged between 1990 and 2005 in Guinea-Bissau: an effect of high chloroquine dosage? Infect Genet Evol 7:555-561
56. Newton PN, Fernandez FM, Plancon A, Mildenhall DC, Green MD, Ziyong L, Christophel EM, Phanouvong S, Howells S, McIntosh E, Laurin P, Blum N, Hampton CY, Faure K, Nyadong L, Soong CW, Santoso B, Zhiguang W, Newton J, Palmer K 2008 A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 5:e32 (Pubitemid 351317652)
57. Atemnkeng MA, De Cock K, Plaizier-Vercammen J 2007 Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Trop Med Int Health 12:68-74 (Pubitemid 44973856)
58. Bate R, Coticelli P, Tren R, Attaran 2008 A Antimalarial drug quality in the most severely malarious parts of Africa-a six country study. PLoS ONE 3:e2132 (Pubitemid 352025174)
59. Hastings IM 2006 Complex dynamics and stability of resistance to antimalarial drugs. Parasitology 132:615-624
60. Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, Niare-Doumbo S, Coulibaly D, Kone AK, Cissoko Y, Tekete M, Fofana B, Dicko A, Diallo DA, Wellems TE, Kwiatkowski D, Plowe CV 2003 Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria 1. Am J Trop Med Hyg 69:558-563
61. Laufer MK, van Oosterhout JJ, Thesing PC, Dzinjalamala FK, Hsi T, Beraho L, Graham SM, Taylor TE, Plowe CV 2007 Malaria treatment efficacy among people living with HIV: the role of host and parasite factors. Am J Trop Med Hyg 77:627-632 (Pubitemid 351844282)
62. Hoffman SL, Masbar S, Hussein PR, Soewarta A, Harun S, Marwoto HA, Campbell JR, Smrkovski L, Purnomo, Wiady I 1984 Absence of malaria mortality in villagers with chloroquine-resistant Plasmodium falciparum treated with chloroquine. Trans R Soc Trop Med Hyg 78:175-178
63. Min-Oo G, Gros P 2005 Erythrocyte variants and the nature of their malaria protective effect 6. Cell Microbiol 7:753-763 (Pubitemid 40740372)
64. Ittarat W, Looareesuwan S, Pootrakul P, Sumpunsirikul P, Vattanavibool P, Meshnick SR 1998 Effects of alpha-thalassemia on pharmacokinetics of the antimalarial agent artesunate. Antimicrob Agents Chemother 42:2332-2335 (Pubitemid 28420373)
65. Kamchonwongpaisan S, Chandra-ngam G, Avery MA, Yuthavong Y 1994 Resistance to artemisinin of malaria parasites (Plasmodium falciparum) infecting alpha-thalassemic erythrocytes in vitro. Competition in drug accumulation with uninfected erythrocytes 1. J Clin Invest 93:467-473 (Pubitemid 24072783)
66. Mockenhaupt FP, May J, Bergqvist Y, Meyer CG, Falusi AG, Bienzle U 2001 Evidence for a reduced effect of chloroquine against Plasmodium falciparum in alpha-thalassaemic children. Trop Med Int Health 6:102-107
67. Laufer MK, Plowe CV 2007 The Interaction between HIV and malaria in Africa. Curr Infect Dis Rep 9:47-54
68. Van Geertruyden JP, Menten J, Colebunders R, Korenromp E, D'Alessandro U 2008 The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance. Malar J 7:134
69. Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, Seila S, Lim C, Incardona S, Lim P, Sem R, Socheat D, Christophel EM, Ringwald P 2006 Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 11:1360-1366 (Pubitemid 44289723)
70. Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, Nakavej A, Wongsrichanalai C 2006 In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health 11:211-219
71. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM 2008 Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619-2620
72. Sibley CH, Barnes KI, Watkins WM, Plowe CV 2008 A network to monitor antimalarial drug resistance: a plan for moving forward. Trends Parasitol 24:43-48